REGN Regeneron Pharmaceuticals, Inc.
Stock · NasdaqGS · United States · Healthcare · US75886F1075
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Regeneron Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
904.35 USD
+0.16%
52-week range
591.52 – 991.73
Dividend yield0.42%
Market cap93.4B
NowoTrade score
50 Grade B
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:12. Information, not advice.
Results
Next results
28 Jan 2027
in 82 days · 08:00 · estimate 25.39
Last results
20.07 vs 16.25 estimated
30 Oct 2026 · Beat +23.5%
Beat the estimate
10 of 12
2 missed · 0 in line · 6 beats in a row
Average surprise
+14.7%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 28 Jan 2027 08:00 | 25.39 | — | — | Upcoming |
| 30 Oct 2026 06:00 | 16.25 | 20.07 | +23.5% | Beat |
| 30 Jul 2026 06:00 | 10.21 | 14.29 | +40.0% | Beat |
| 29 Apr 2026 06:00 | 8.90 | 9.47 | +6.4% | Beat |
| 30 Jan 2026 06:00 | 10.75 | 11.44 | +6.4% | Beat |
| 28 Oct 2025 06:00 | 9.64 | 11.83 | +22.7% | Beat |
| 01 Aug 2025 06:00 | 8.44 | 12.89 | +52.7% | Beat |
| 29 Apr 2025 06:00 | 8.48 | 8.22 | -3.0% | Miss |
| 04 Feb 2025 06:00 | 11.19 | 12.07 | +7.8% | Beat |
| 31 Oct 2024 06:00 | 11.70 | 12.46 | +6.5% | Beat |
| 01 Aug 2024 06:00 | 10.62 | 11.56 | +8.8% | Beat |
| 02 May 2024 06:00 | 10.10 | 9.55 | -5.4% | Miss |
| 02 Feb 2024 06:00 | 10.75 | 11.86 | +10.4% | Beat |
| 02 Nov 2023 06:00 | 10.78 | 11.59 | +7.6% | Beat |
| 03 Aug 2023 06:00 | 9.90 | 10.24 | +3.5% | Beat |
| 04 May 2023 06:00 | 9.56 | 10.09 | +5.6% | Beat |
| 03 Feb 2023 06:00 | 10.01 | 12.56 | +25.5% | Beat |
| 03 Nov 2022 06:00 | 9.48 | 11.14 | +17.6% | Beat |
| 03 Aug 2022 06:00 | 8.76 | 9.77 | +11.6% | Beat |
| 04 May 2022 06:00 | 9.80 | 11.49 | +17.3% | Beat |
| 04 Feb 2022 06:00 | 20.30 | 23.72 | +16.9% | Beat |
| 04 Nov 2021 06:00 | 9.94 | 15.37 | +54.7% | Beat |
| 05 Aug 2021 06:00 | 17.71 | 25.80 | +45.7% | Beat |
| 06 May 2021 06:00 | 8.68 | 9.89 | +14.0% | Beat |
| 05 Feb 2021 06:00 | 8.29 | 9.53 | +15.0% | Beat |
| 05 Nov 2020 06:00 | 6.99 | 8.36 | +19.6% | Beat |
| 05 Aug 2020 06:00 | 5.97 | 7.16 | +20.0% | Beat |
| 05 May 2020 07:00 | 6.09 | 6.60 | +8.5% | Beat |
| 06 Feb 2020 06:00 | 7.17 | 7.50 | +4.6% | Beat |
| 05 Nov 2019 06:00 | 6.40 | 6.67 | +4.3% | Beat |
| 06 Aug 2019 06:00 | 5.42 | 6.02 | +11.2% | Beat |
| 07 May 2019 06:00 | 5.52 | 4.45 | -19.4% | Miss |
| 06 Feb 2019 06:00 | 5.60 | 6.84 | +22.1% | Beat |
| 06 Nov 2018 06:00 | 5.06 | 5.87 | +15.9% | Beat |
| 02 Aug 2018 06:00 | 4.68 | 5.45 | +16.4% | Beat |
| 03 May 2018 06:00 | 4.34 | 4.67 | +7.5% | Beat |
| 08 Feb 2018 06:00 | 4.57 | 5.23 | +14.4% | Beat |
| 08 Nov 2017 06:00 | 3.82 | 3.99 | +4.4% | Beat |
| 03 Aug 2017 06:00 | 3.18 | 4.17 | +31.0% | Beat |
| 04 May 2017 06:00 | 3.07 | 2.92 | -4.8% | Miss |
| 09 Feb 2017 07:00 | 3.05 | 3.04 | -0.3% | In line |
| 04 Nov 2016 06:00 | 2.70 | 3.13 | +16.0% | Beat |
| 04 Aug 2016 06:00 | 2.65 | 2.82 | +6.4% | Beat |
| 05 May 2016 06:00 | 2.55 | 2.57 | +0.8% | In line |
| 09 Feb 2016 06:00 | 3.36 | 2.83 | -15.8% | Miss |
| 04 Nov 2015 06:00 | 3.20 | 3.47 | +8.3% | Beat |
| 04 Aug 2015 06:00 | 2.78 | 2.89 | +4.0% | Beat |
| 07 May 2015 06:00 | 2.69 | 2.88 | +7.2% | Beat |
| 10 Feb 2015 06:00 | 2.83 | 2.79 | -1.5% | Miss |
| 04 Nov 2014 06:00 | 2.57 | 2.52 | -2.1% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 14.3B | +1.0% | 4.5B | 31.4% | 41.48 | +8.2% | 3.8B |
| 2024 | 14.2B | +8.3% | 4.4B | 31.1% | 38.34 | +10.3% | 3.5B |
| 2023 | 13.1B | +7.8% | 4B | 30.1% | 34.77 | -9.0% | 3.7B |
| 2022 | 12.2B | — | 4.3B | 35.6% | 38.22 | — | 3.4B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 05 Apr 2024 | 939.31 | 949.83 | 934.87 | 942.70 | +0.61% | 363,500 | |
| 04 Apr 2024 | 962.20 | 962.20 | 935.36 | 937.02 | -1.46% | 410,800 | |
| 03 Apr 2024 | 955.00 | 961.68 | 950.43 | 950.95 | -0.39% | 413,200 | |
| 02 Apr 2024 | 961.44 | 961.44 | 951.02 | 954.68 | -1.51% | 438,100 | |
| 01 Apr 2024 | 964.73 | 970.20 | 954.09 | 969.31 | +0.71% | 360,600 | |
| 28 Mar 2024 | 970.38 | 970.79 | 959.25 | 962.49 | -0.39% | 461,800 | |
| 27 Mar 2024 | 971.04 | 976.75 | 962.41 | 966.30 | +0.29% | 314,800 | |
| 26 Mar 2024 | 961.99 | 966.68 | 957.78 | 963.55 | +0.26% | 386,800 | |
| 25 Mar 2024 | 954.01 | 964.98 | 952.47 | 961.09 | -0.64% | 322,300 | |
| 22 Mar 2024 | 973.00 | 977.39 | 966.47 | 967.24 | -0.08% | 274,400 | |
| 21 Mar 2024 | 974.75 | 979.26 | 968.00 | 968.01 | +0.11% | 435,100 | |
| 20 Mar 2024 | 959.06 | 967.20 | 947.37 | 966.96 | +0.34% | 579,300 | |
| 19 Mar 2024 | 965.11 | 969.16 | 959.14 | 963.66 | +0.39% | 365,300 | |
| 18 Mar 2024 | 970.00 | 970.71 | 959.49 | 959.92 | -0.47% | 360,200 | |
| 15 Mar 2024 | 956.47 | 968.51 | 953.72 | 964.47 | +0.57% | 1,090,500 | |
| 14 Mar 2024 | 966.30 | 969.18 | 950.97 | 959.04 | -0.67% | 507,300 | |
| 13 Mar 2024 | 979.82 | 979.82 | 963.83 | 965.47 | -0.53% | 386,200 | |
| 12 Mar 2024 | 964.44 | 975.93 | 963.00 | 970.57 | +0.64% | 359,000 | |
| 11 Mar 2024 | 971.09 | 979.80 | 960.44 | 964.44 | -0.45% | 355,600 | |
| 08 Mar 2024 | 973.34 | 976.00 | 962.82 | 968.83 | -0.46% | 354,400 | |
| 07 Mar 2024 | 971.13 | 979.25 | 969.88 | 973.31 | +0.12% | 380,500 | |
| 06 Mar 2024 | 959.23 | 974.18 | 955.56 | 972.10 | +0.71% | 366,800 | |
| 05 Mar 2024 | 972.72 | 977.67 | 953.29 | 965.21 | -0.62% | 397,500 | |
| 04 Mar 2024 | 982.82 | 985.21 | 966.22 | 971.19 | -1.18% | 455,600 | |
| 01 Mar 2024 | 967.50 | 988.13 | 966.09 | 982.82 | +1.73% | 370,500 |
Page 27 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Mary Tyler Moore Vision Initiative Welcomes Regeneron and Adaptive Sensory Technology to Its Consortium (opens in a new tab) 05 Nov 2026 16:06
- Strategic Exercise: Christine A Poon Decides To Exercise Options Worth $4.39M At Regeneron Pharmaceuticals (opens in a new tab) Benzinga · 05 Nov 2026 11:01
- At Regeneron Pharmaceuticals, George L Sing Chooses To Exercise Options, Resulting In $8.53M (opens in a new tab) Benzinga · 05 Nov 2026 11:01
- Is Regeneron Stock Riskier Than It Looks? (opens in a new tab) Trefis · 05 Nov 2026 10:36
- Is Regeneron Stock Increasing Your Market Risk? (opens in a new tab) Trefis · 04 Nov 2026 22:22
- Was There Any Sign Regeneron Stock Would Run? (opens in a new tab) Trefis · 04 Nov 2026 20:59
- Moderna Soars 8% on Early Multiple Myeloma Data for Its Three-in-One mRNA Therapy (opens in a new tab) TIKR · 04 Nov 2026 16:41
- Why Regeneron (REGN) Might be Well Poised for a Surge (opens in a new tab) Zacks · 04 Nov 2026 16:20
- REGN vs. ILMN: Which Stock Is the Better Value Option? (opens in a new tab) Zacks · 04 Nov 2026 15:40
- Regeneron Pharmaceuticals (NASDAQ:REGN) Looks Undervalued Under the Decent Value Framework (opens in a new tab) ChartMill · 03 Nov 2026 12:52
- UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC’s ‘Final Trades’ (opens in a new tab) Benzinga · 03 Nov 2026 08:06
- Regeneron Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 03 Nov 2026 02:50
- Regeneron Announces Investor Conference Presentations (opens in a new tab) 02 Nov 2026 21:05
- REGN Q3 deep dive: pipeline progress and core brands drive outperformance (opens in a new tab) StockStory · 02 Nov 2026 19:33
- Regeneron's 'Strong Commercial' Q3 Underscores Core Business Health, RBC Capital Markets Says (opens in a new tab) MT Newswires · 02 Nov 2026 16:40
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 902.90 USD
- Market cap
- 93.4B
- Dividend yield
- 0.42%
- Payout ratio
- 8%
- Last dividend
- 0.9400 USD · 20 Nov 2026
- Next ex-dividend date
- 20 Nov 2026
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 18 Aug 2026 | 0.9400 USD |
| 20 May 2026 | 0.9400 USD |
| 20 Feb 2026 | 0.9400 USD |
| 20 Nov 2025 | 0.8800 USD |
| 18 Aug 2025 | 0.8800 USD |
| 20 May 2025 | 0.8800 USD |
| 20 Feb 2025 | 0.8800 USD |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble. | 1.7 / 25 |
|
| Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover. | 25.0 / 25 |
|
| Dividend growth How many years in a row the dividend has risen, and how fast. | 5.2 / 15 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 12.2 / 15 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.3 / 10 |
|
| Analysts How far the analysts' average target is from today's price. | 3.0 / 5 |
|
- Total debt has risen three years in a row
Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 80% of the figures (grade B). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 19.99× | Fair | 31.09× |
| P/E (forward) | 12.79× | Good | 14.98× |
| Price / book | 2.71× | Fair | 3.87× |
| Price / sales | 5.54× | Weak | 3.42× |
| EV / EBITDA | 14.88× | Fair | 13.09× |
| Free cash flow yield | 2.8% | Fair | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 46.7% | Good | 59.2% |
| Operating margin | 40.5% | Good | 7.8% |
| Net margin | 28.5% | Good | 3.4% |
| Return on equity | 14.9% | Fair | 5.7% |
| Return on assets | 7.6% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 5.6% | Fair | 10.8% |
| EPS growth / year | 2.8% | Weak | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.08× | Good | 0.46× |
| Net debt / EBITDA | -1.17× | Good | 1.48× |
| Interest cover | 84.52× | Good | 3.26× |
| Current ratio | 3.35× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 8.2% | Good | 0% |
| Payout of free cash flow | 14.4% | Good | 30.1% |
| Payout of free cash flow (3 years) | 3.4% | Good | — |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow REGN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.